Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 5 | 2023 | 149 | 2.230 |
Why?
|
| Coronary Disease | 9 | 2015 | 50 | 1.660 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 53 | 1.440 |
Why?
|
| Cisplatin | 2 | 2023 | 58 | 1.390 |
Why?
|
| Cardiovascular Diseases | 6 | 2020 | 321 | 1.370 |
Why?
|
| Secondary Prevention | 5 | 2020 | 51 | 1.270 |
Why?
|
| Cardiology | 5 | 2021 | 44 | 1.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 245 | 1.190 |
Why?
|
| Cardiac Rehabilitation | 4 | 2021 | 7 | 1.100 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 552 | 1.070 |
Why?
|
| Coronary Artery Disease | 4 | 2017 | 135 | 0.930 |
Why?
|
| Acute Coronary Syndrome | 4 | 2021 | 12 | 0.860 |
Why?
|
| Acrylamides | 2 | 2020 | 3 | 0.830 |
Why?
|
| Aniline Compounds | 2 | 2020 | 35 | 0.830 |
Why?
|
| Humans | 45 | 2023 | 27074 | 0.790 |
Why?
|
| Heart Failure | 7 | 2021 | 151 | 0.760 |
Why?
|
| Exercise Test | 3 | 2018 | 118 | 0.750 |
Why?
|
| Carboplatin | 1 | 2021 | 26 | 0.720 |
Why?
|
| Benzimidazoles | 1 | 2021 | 6 | 0.720 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2021 | 5 | 0.720 |
Why?
|
| Paclitaxel | 1 | 2021 | 50 | 0.710 |
Why?
|
| Standard of Care | 1 | 2020 | 14 | 0.710 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 243 | 0.680 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 8 | 0.670 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 15 | 0.640 |
Why?
|
| Medicine | 2 | 2008 | 11 | 0.610 |
Why?
|
| Physicians, Family | 2 | 2008 | 6 | 0.610 |
Why?
|
| Specialization | 2 | 2008 | 15 | 0.610 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2018 | 16 | 0.600 |
Why?
|
| Lipocalin-2 | 1 | 2018 | 1 | 0.600 |
Why?
|
| Cystatin C | 1 | 2018 | 3 | 0.600 |
Why?
|
| Life Style | 3 | 2019 | 186 | 0.590 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 38 | 0.570 |
Why?
|
| Hypertension | 2 | 2019 | 192 | 0.570 |
Why?
|
| Mutation | 1 | 2019 | 348 | 0.570 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 198 | 0.560 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2017 | 2 | 0.550 |
Why?
|
| Taxoids | 1 | 2017 | 10 | 0.550 |
Why?
|
| Apoptosis | 2 | 2022 | 213 | 0.550 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 261 | 0.550 |
Why?
|
| ErbB Receptors | 3 | 2023 | 54 | 0.520 |
Why?
|
| Cell Proliferation | 1 | 2017 | 175 | 0.520 |
Why?
|
| Aged | 20 | 2023 | 8997 | 0.490 |
Why?
|
| Depression | 3 | 2018 | 444 | 0.480 |
Why?
|
| Neoplasms | 1 | 2018 | 237 | 0.480 |
Why?
|
| Coronary Artery Bypass | 1 | 2014 | 27 | 0.450 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 131 | 0.450 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 44 | 0.440 |
Why?
|
| Middle Aged | 17 | 2021 | 8923 | 0.440 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 23 | 0.440 |
Why?
|
| Return to Work | 1 | 2014 | 65 | 0.430 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 40 | 0.430 |
Why?
|
| Male | 20 | 2023 | 14772 | 0.420 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 409 | 0.400 |
Why?
|
| Female | 19 | 2021 | 15213 | 0.390 |
Why?
|
| Critical Pathways | 1 | 2011 | 19 | 0.360 |
Why?
|
| Program Evaluation | 3 | 2017 | 120 | 0.360 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 18 | 0.360 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 310 | 0.340 |
Why?
|
| Risk Factors | 11 | 2019 | 2302 | 0.330 |
Why?
|
| Chest Pain | 1 | 2009 | 19 | 0.330 |
Why?
|
| Prognosis | 4 | 2021 | 785 | 0.330 |
Why?
|
| Mass Screening | 1 | 2011 | 167 | 0.320 |
Why?
|
| Australia | 8 | 2021 | 40 | 0.320 |
Why?
|
| Smartphone | 2 | 2021 | 15 | 0.320 |
Why?
|
| Models, Statistical | 1 | 2009 | 127 | 0.320 |
Why?
|
| Medication Adherence | 1 | 2009 | 49 | 0.310 |
Why?
|
| Exercise Therapy | 2 | 2021 | 88 | 0.300 |
Why?
|
| Biomarkers | 3 | 2020 | 562 | 0.290 |
Why?
|
| Young Adult | 4 | 2021 | 1994 | 0.280 |
Why?
|
| Death, Sudden | 1 | 2006 | 7 | 0.260 |
Why?
|
| Quality of Life | 4 | 2021 | 629 | 0.260 |
Why?
|
| Adult | 8 | 2021 | 7831 | 0.240 |
Why?
|
| Risk Assessment | 5 | 2019 | 624 | 0.230 |
Why?
|
| Prospective Studies | 6 | 2018 | 1778 | 0.230 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 46 | 0.230 |
Why?
|
| Prevalence | 2 | 2019 | 443 | 0.210 |
Why?
|
| Cetuximab | 1 | 2023 | 6 | 0.210 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 36 | 0.210 |
Why?
|
| Laryngeal Neoplasms | 1 | 2023 | 34 | 0.210 |
Why?
|
| Counseling | 2 | 2017 | 42 | 0.200 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 7 | 0.200 |
Why?
|
| Nose Neoplasms | 1 | 2022 | 40 | 0.190 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 65 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 4777 | 0.180 |
Why?
|
| Radiosurgery | 1 | 2021 | 34 | 0.180 |
Why?
|
| DDT | 1 | 2020 | 1 | 0.180 |
Why?
|
| Insulin-Secreting Cells | 1 | 2020 | 12 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 172 | 0.170 |
Why?
|
| Societies, Medical | 2 | 2020 | 121 | 0.170 |
Why?
|
| Comorbidity | 4 | 2021 | 481 | 0.170 |
Why?
|
| Proteomics | 1 | 2020 | 89 | 0.170 |
Why?
|
| United Kingdom | 1 | 2019 | 47 | 0.170 |
Why?
|
| Blood Circulation | 1 | 2019 | 1 | 0.160 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 4 | 0.160 |
Why?
|
| Circulating Tumor DNA | 1 | 2019 | 6 | 0.160 |
Why?
|
| Retrospective Studies | 5 | 2023 | 3538 | 0.160 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 56 | 0.160 |
Why?
|
| France | 1 | 2019 | 12 | 0.160 |
Why?
|
| Walking Speed | 1 | 2019 | 41 | 0.160 |
Why?
|
| Diastole | 1 | 2019 | 28 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 33 | 0.160 |
Why?
|
| Waist Circumference | 1 | 2019 | 35 | 0.160 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 19 | 0.160 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 38 | 0.160 |
Why?
|
| Stroke Volume | 1 | 2019 | 54 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 10 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2021 | 3485 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 168 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 69 | 0.150 |
Why?
|
| Bias | 2 | 2008 | 32 | 0.150 |
Why?
|
| American Heart Association | 1 | 2018 | 16 | 0.150 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 474 | 0.150 |
Why?
|
| Mouth | 1 | 2018 | 14 | 0.150 |
Why?
|
| Peptide Fragments | 1 | 2019 | 76 | 0.150 |
Why?
|
| Pharynx | 1 | 2018 | 12 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 86 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 90 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 39 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2018 | 81 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 237 | 0.150 |
Why?
|
| Aspirin | 1 | 2018 | 83 | 0.140 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 133 | 0.140 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2017 | 4 | 0.140 |
Why?
|
| Coronary Vessels | 1 | 2017 | 34 | 0.140 |
Why?
|
| Caspases | 1 | 2017 | 26 | 0.140 |
Why?
|
| Exercise | 1 | 2021 | 450 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 207 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 129 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2019 | 443 | 0.140 |
Why?
|
| Health Behavior | 3 | 2021 | 159 | 0.140 |
Why?
|
| Blotting, Western | 1 | 2017 | 147 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2019 | 1890 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2019 | 458 | 0.130 |
Why?
|
| United States | 3 | 2018 | 2035 | 0.130 |
Why?
|
| Telephone | 2 | 2014 | 26 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 891 | 0.130 |
Why?
|
| Patient Compliance | 3 | 2016 | 150 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 205 | 0.120 |
Why?
|
| Calcium | 1 | 2017 | 371 | 0.110 |
Why?
|
| Depressive Disorder | 2 | 2015 | 177 | 0.110 |
Why?
|
| Elective Surgical Procedures | 1 | 2013 | 37 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2013 | 117 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2013 | 62 | 0.100 |
Why?
|
| New Zealand | 3 | 2020 | 11 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 161 | 0.100 |
Why?
|
| Affect | 1 | 2011 | 60 | 0.090 |
Why?
|
| Family Practice | 1 | 2009 | 15 | 0.080 |
Why?
|
| Medical Audit | 1 | 2009 | 5 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2009 | 42 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 30 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 18 | 0.080 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 27 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 26 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 51 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2009 | 100 | 0.080 |
Why?
|
| Telemedicine | 1 | 2011 | 97 | 0.080 |
Why?
|
| Exercise Tolerance | 2 | 2021 | 31 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 55 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2013 | 916 | 0.070 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 18 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2006 | 28 | 0.070 |
Why?
|
| Incidence | 2 | 2019 | 759 | 0.070 |
Why?
|
| Time Factors | 1 | 2009 | 1433 | 0.060 |
Why?
|
| Cholesterol | 2 | 2003 | 64 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 342 | 0.060 |
Why?
|
| Hypercholesterolemia | 2 | 2002 | 24 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1792 | 0.060 |
Why?
|
| Immobilization | 1 | 2023 | 13 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2023 | 9 | 0.050 |
Why?
|
| Laryngectomy | 1 | 2023 | 21 | 0.050 |
Why?
|
| Neck | 1 | 2023 | 26 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 35 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2003 | 43 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 51 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 61 | 0.050 |
Why?
|
| Victoria | 2 | 2019 | 8 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 36 | 0.050 |
Why?
|
| Cardiovascular Agents | 2 | 2013 | 24 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 8 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2002 | 14 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 4 | 0.050 |
Why?
|
| Walk Test | 1 | 2021 | 10 | 0.050 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 14 | 0.050 |
Why?
|
| Length of Stay | 1 | 2023 | 313 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 206 | 0.050 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2020 | 10 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 35 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 420 | 0.040 |
Why?
|
| Cell Survival | 1 | 2020 | 121 | 0.040 |
Why?
|
| Health Promotion | 1 | 2002 | 143 | 0.040 |
Why?
|
| Cell Line | 1 | 2020 | 273 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2021 | 295 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 87 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 19 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 74 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 271 | 0.040 |
Why?
|
| Echocardiography | 1 | 2019 | 73 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 683 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 144 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 141 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 108 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 158 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 36 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2017 | 21 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 464 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2018 | 406 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 123 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 257 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2019 | 214 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 102 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 77 | 0.030 |
Why?
|
| Text Messaging | 1 | 2016 | 13 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 766 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 102 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 587 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 879 | 0.030 |
Why?
|
| Independent Living | 1 | 2018 | 322 | 0.030 |
Why?
|
| Anxiety | 1 | 2015 | 156 | 0.030 |
Why?
|
| Social Support | 1 | 2015 | 196 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2013 | 11 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 47 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2013 | 26 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2013 | 72 | 0.030 |
Why?
|
| Hypolipidemic Agents | 2 | 2003 | 26 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 35 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 57 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 220 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2006 | 21 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 34 | 0.020 |
Why?
|
| Aftercare | 1 | 2006 | 24 | 0.020 |
Why?
|
| Physical Examination | 1 | 2006 | 116 | 0.020 |
Why?
|
| Palliative Care | 1 | 2006 | 110 | 0.020 |
Why?
|
| Allied Health Personnel | 1 | 2003 | 7 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 2003 | 25 | 0.010 |
Why?
|
| Europe | 1 | 2002 | 58 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 139 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 260 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 329 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2002 | 167 | 0.010 |
Why?
|
| Obesity | 1 | 2002 | 311 | 0.010 |
Why?
|